All In Biotech

Drug Trial Radar · NCT07033455

A Trial of HRS-1893 in Healthy Volunteers

A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of HRS-1893 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Jun 25, 2025

Primary completion

Sep 5, 2025

Study completion Oct 30, 2025

Sponsor

Lead sponsor
Atridia Pty Ltd.Industry
Sponsor type
Industry
First posted
Jun 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and PK characteristics of a single oral dose of HRS-1893 in healthy voluunters.

Conditions

  • Hypertrophic Cardiomyopathy

Interventions

  • HRS-1893Drug

    Single dose of HRS-1893 orally administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK profile of HRS-1893 after a single oral (PO) administrationTime frame: Day 8
  2. PK profile of HRS-1893 after a single oral (PO) administrationTime frame: Day 8
  3. PK profile of HRS-1893 after a single oral (PO) administrationTime frame: Day 8
  4. PK profile of HRS-1893 after a single oral (PO) administrationTime frame: Day 8
  5. PK profile of HRS-1893 after a single oral (PO) administrationTime frame: Day 8
  6. PK profile of HRS-1893 after a single oral (PO) administrationTime frame: Day 8
  7. PK profile of HRS-1893 after a single oral (PO) administrationTime frame: Day 8
  8. Cumulative amount of drug excreted in urine of HRS-1893 after a single oral administrationTime frame: Day 8
  9. Cumulative percentage of dose recovered in urine of HRS-1893 after a single oral administration:Time frame: Day 8
  10. Renal clearance of HRS-1893 after a single oral administrationTime frame: Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.